TherapeuticsMD AI Stock Analysis
Want to see TXMD full AI Analyst Report?
TherapeuticsMD (TXMD) AI Stock Analysis
TherapeuticsMD
(NASDAQ:TXMD)
TXMD scores in the lower-middle range, held back primarily by a very small and shrinking operating business: trailing revenue of $2.5 million is down 24% year over year and the company still runs an operating loss, leaving earnings quality and visibility low. Valuation compounds the caution, with a P/E near 231 that reflects negligible earnings and no dividend. Technically, the stock trades below its 50-, 100-, and 200-day moving averages with a negative MACD, signalling a persistent downtrend. Partially offsetting these risks is a genuinely repaired financial structure - debt down to $4.2 million, positive equity of $27.6 million, $10.4 million of cash, and $3.4 million of free cash flow - alongside an encouraging third-quarter report showing higher net income and 60.6% license revenue growth. Overall, a de-risked but strategically uncertain micro-cap whose future hinges on how it deploys its cash and royalty streams.
TherapeuticsMD (TXMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $21.64M
- Dividend Yield
- ―
- Average Volume (3M)
- 24.41K
- Price to Earnings (P/E)
- 230.9
- Beta (1Y)
- 1.17
- Revenue Growth
- 33.94%
- EPS Growth
- -59.77%
- Country
- US
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
TherapeuticsMD Business Overview & Revenue Model
Company Description
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradi...
How the Company Makes Money
TherapeuticsMD has generated revenue primarily through out-licensing/partnering arrangements for its product portfolio rather than through building a fully integrated, long-term direct commercial sales model. Under these types of agreements, the comp...
TherapeuticsMD Financial Statement Overview
Summary
A mixed picture dominated by extremely small scale. The income statement is the key weakness (score 28): trailing revenue of just $2.5 million is down roughly 24% year over year, the business still posts an operating loss of about -$3.5 million, and the near-breakeven $0.1 million net income comes from items below the operating line. The balance sheet is far stronger (score 64), with debt cut to $4.2 million from nearly $198 million, equity restored to a positive $27.6 million, and a conservative debt-to-equity ratio of 0.15. Cash flow (score 61) has turned decisively positive, with $3.4 million of operating cash flow converting fully to free cash flow under the asset-light royalty model. Net: a de-risked, clean financial structure, but an operating engine that is tiny, contracting, and concentrated in a narrow royalty stream.
Income Statement
28NegativeBalance Sheet
64PositiveCash Flow
61Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.75M | 3.02M | 1.76M | 1.30M | 69.96M | 2.57M |
| Gross Profit | 3.08M | 3.02M | 1.76M | 1.30M | 68.57M | 1.17M |
| EBITDA | -4.26M | -3.02M | -4.33M | -7.60M | 11.86M | -78.84M |
| Net Income | 122.00K | -569.00K | -2.18M | -10.28M | 112.00M | -172.41M |
Balance Sheet | ||||||
| Total Assets | 37.93M | 37.66M | 38.82M | 43.31M | 90.46M | 169.47M |
| Cash, Cash Equivalents and Short-Term Investments | 10.45M | 7.48M | 5.06M | 4.33M | 38.07M | 64.91M |
| Total Debt | 4.21M | 6.10M | 7.17M | 8.01M | 8.76M | 197.69M |
| Total Liabilities | 10.31M | 10.78M | 11.45M | 14.02M | 55.31M | 263.09M |
| Stockholders Equity | 27.62M | 26.88M | 27.37M | 29.29M | 35.14M | -93.62M |
Cash Flow | ||||||
| Free Cash Flow | 3.36M | 2.42M | 732.00K | 0 | -4.43M | -147.84M |
| Operating Cash Flow | 3.36M | 2.42M | 732.00K | -48.14M | -4.08M | -147.81M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 223.48M | -2.22M |
| Financing Cash Flow | 0 | 0 | 0 | 3.15M | -235.21M | 134.67M |
TherapeuticsMD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXMD, the sentiment is Neutral. The current price of 1.87 is above the 20-day moving average (MA) of 1.81, below the 50-day MA of 1.97, and below the 200-day MA of 2.08, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 51.45 is Neutral, neither overbought nor oversold. The STOCH value of 90.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TXMD.
TherapeuticsMD Risk Analysis
TherapeuticsMD disclosed 49 risk factors in its most recent earnings report. TherapeuticsMD reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksTherapeuticsMD Peers Comparison
Overall Rating
AYTU62Neutral
TXMD47Neutral
RDHL42Neutral
PRPH41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 62Neutral | $19.35M | -1.30 | -52.89% | ― | -13.27% | 27.11% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $21.64M | 230.86 | 0.45% | ― | 33.94% | -59.77% | |
| 42Neutral | $3.33M | -0.38 | -438.17% | ― | ― | ― | |
| 41Neutral | $88.25K | -0.00 | -1358.66% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TXMD | Therapeuticsmd Inc | 1.87 | 0.35 | 23.03% | |
| PRPH | Prophase Labs | 0.01 | -2.64 | -99.62% | |
| RDHL | RedHill Biopharma Ltd | 0.38 | -0.67 | -63.94% | |
| AYTU | Aytu BioScience | 1.78 | -0.20 | -10.10% | |
| GELS | Gelteq Limited | 0.38 | -0.56 | -59.57% |
TherapeuticsMD Corporate Events
TherapeuticsMD Reports Third-Quarter Net Income and Revenue Growth
PositiveTherapeuticsMD is a pharmaceutical royalty company that primarily collects royalties from licensees; it changed from a women’s healthcare company in December 2022 and no longer engages in research and development or commercial operations. On November...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
